Abera Bioscience Q2 FY26 loss before financial items widens to SEK 5.56 million; net sales show no revenue

Reuters2026/08/20 05:54

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Abera Bioscience posted a loss after financial items of SEK 5.56 million in Q2 2026, widening from SEK 833,000 a year earlier.
Loss per share widened to SEK 0.27; net sales were nil.
Other operating income fell to SEK 1.56 million from SEK 4.3 million in the year-ago quarter.
Equity ratio rose 24 percentage points to 80%.
GMP production of Ab-01.12 clinical trial material was completed; a Phase I application was submitted in the Netherlands after quarter-end.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abera Bioscience AB published the original content used to generate this news brief via Cision (Ref. ID: 202608200150BITN____UKPR__SV_20260820-BIT-9941-0) on August 20, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Abera Bioscience Q2 FY26 loss before financial items widens to SEK 5.56 million; net sales show no revenue

You may also like

Crypto prices